Haixin Yu1, Yan Wang1, Qian Yu2, Haiyan Zhang2, Wenduan Ma1, Shengtao Shang1, Donglin Wang3. 1. Department of Thoracic Surgery, China-Japan Union Hospital of Jilin University Changchun 130033, China. 2. Department of Pharmacy, China-Japan Union Hospital of Jilin University Changchun 130033, China. 3. Green Garden District Changchun City Hospital No. 1015, Chuncheng Avenue, Changchun 130062, China.
Abstract
PURPOSE: We aimed to figure out the difference of serum hepatocyte growth factor (S-HGF) level between benign and malignant solitary pulmonary nodules (SPNs) patients. METHODS: The study comprised 42 serum samples from SPNs patients and 10 serum samples of healthy donors. The HGF level was measured by the commercially enzyme-linked immunosorbent assay (ELISA) kit. RESULTS: By statistical analysis, the S-HGF levels of the malignant SPNs patients were significantly higher than that of control group (P < 0.05). Moreover, the levels of S-HGF in malignant group were also significantly higher than that in benign group (P < 0.05), while there was no significant difference between the benign and control group (P > 0.05). The levels of S-HGF were also shown no statistically significant difference (P > 0.05) in different pathologic types of lung cancer patients. In addition, the incidence of malignant SPNs increased when the S-HGF level ≥ 250 pg/ml. CONCLUSION: The detection of S-HGF level may be a new detection method used for the rapid diagnosis of benign and malignant SPNs.
PURPOSE: We aimed to figure out the difference of serum hepatocyte growth factor (S-HGF) level between benign and malignant solitary pulmonary nodules (SPNs) patients. METHODS: The study comprised 42 serum samples from SPNs patients and 10 serum samples of healthy donors. The HGF level was measured by the commercially enzyme-linked immunosorbent assay (ELISA) kit. RESULTS: By statistical analysis, the S-HGF levels of the malignant SPNs patients were significantly higher than that of control group (P < 0.05). Moreover, the levels of S-HGF in malignant group were also significantly higher than that in benign group (P < 0.05), while there was no significant difference between the benign and control group (P > 0.05). The levels of S-HGF were also shown no statistically significant difference (P > 0.05) in different pathologic types of lung cancerpatients. In addition, the incidence of malignant SPNs increased when the S-HGF level ≥ 250 pg/ml. CONCLUSION: The detection of S-HGF level may be a new detection method used for the rapid diagnosis of benign and malignant SPNs.
Authors: Denise R Aberle; Sarah DeMello; Christine D Berg; William C Black; Brenda Brewer; Timothy R Church; Kathy L Clingan; Fenghai Duan; Richard M Fagerstrom; Ilana F Gareen; Constantine A Gatsonis; David S Gierada; Amanda Jain; Gordon C Jones; Irene Mahon; Pamela M Marcus; Joshua M Rathmell; JoRean Sicks Journal: N Engl J Med Date: 2013-09-05 Impact factor: 91.245
Authors: S Nakamura; R Morishita; A Moriguchi; Y Yo; Y Nakamura; S Hayashi; K Matsumoto; K Matsumoto; T Nakamura; J Higaki; T Ogihara Journal: J Hypertens Date: 1998-12 Impact factor: 4.844
Authors: H Tsubouchi; Y Niitani; S Hirono; H Nakayama; E Gohda; N Arakaki; O Sakiyama; K Takahashi; M Kimoto; S Kawakami Journal: Hepatology Date: 1991-01 Impact factor: 17.425